Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

National recommendations of the Working group for laboratory diagnostics of autoimmune diseases of the Croatian Society of Medical Biochemistry and Laboratory Medicine: Assessment of antineutrophil cytoplasmic antibodies (ANCA).

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Croatian Society for Medical Biochemistry and Laboratory Medicine Country of Publication: Croatia NLM ID: 9610305 Publication Model: Print Cited Medium: Internet ISSN: 1846-7482 (Electronic) Linking ISSN: 13300962 NLM ISO Abbreviation: Biochem Med (Zagreb) Subsets: MEDLINE
    • Publication Information:
      Publication: 2012- : Zagreb : Croatian Society for Medical Biochemistry and Laboratory Medicine
      Original Publication: Zagreb : Hrvatsko društvo medicinskih biokemičara
    • Subject Terms:
      Antibodies, Antineutrophil Cytoplasmic*/blood ; Antibodies, Antineutrophil Cytoplasmic*/analysis ; Antibodies, Antineutrophil Cytoplasmic*/immunology ; Autoimmune Diseases*/diagnosis ; Autoimmune Diseases*/immunology ; Autoimmune Diseases*/blood ; Clinical Laboratory Techniques*/standards; Peroxidase/immunology ; Humans ; Croatia ; Societies, Medical ; Quality Control
    • Abstract:
      The family of antineutrophil cytoplasmic antibodies (ANCA) includes autoantibodies targeting proteins within the primary granules of neutrophils and lysosomes of monocytes. So far, proteinase 3 (PR3) and myeloperoxidase (MPO) are considered clinically relevant ANCA specificities. National recommendations for the assessment of ANCA are the outcome of the survey done by the Working group (WG) for laboratory diagnostics of autoimmune diseases of the Croatian Society of Medical Biochemistry and Laboratory Medicine (CSMBLM), where the diversity in the performance of ANCA testing and reporting among the laboratories in Croatia was observed. This document contains recommendations concerning the indications for ANCA testing, preanalytical, analytical and postanalytical issues, including rational algorithm and quality control assurance. The recommendations are based on the International consensus on ANCA testing and reporting as well as other relevant literature in order to help to harmonize ANCA testing. The aim of these recommendations is to improve and harmonize ANCA testing among laboratories in Croatia.
      (Croatian Society of Medical Biochemistry and Laboratory Medicine.)
    • Abstract:
      Potential conflict of interest None declared.
    • References:
      J Immunol Methods. 2018 Jul;458:1-7. (PMID: 29486145)
      Clin Chem Lab Med. 2018 Jan 26;56(2):e39-e42. (PMID: 28755530)
      Ann Rheum Dis. 2016 Apr;76(4):647-653. (PMID: 27481830)
      Clin Chim Acta. 2017 Apr;467:48-50. (PMID: 27262820)
      J Am Soc Nephrol. 2015 Oct;26(10):2314-27. (PMID: 25956510)
      Ann Rheum Dis. 2018 Aug;77(8):1143-1149. (PMID: 29695500)
      Clin Rev Allergy Immunol. 2012 Dec;43(3):211-9. (PMID: 22669754)
      Rheumatology (Oxford). 2012 Jan;51(1):100-9. (PMID: 22039267)
      Clin Chem Lab Med. 2020 Oct 16;59(2):e35-e39. (PMID: 33027040)
      Reumatol Clin (Engl Ed). 2020 Nov - Dec;16(6):473-479. (PMID: 30704921)
      Rheumatology (Oxford). 2017 Sep 1;56(9):1533-1541. (PMID: 28541581)
      Biochem Med (Zagreb). 2016 Oct 15;26(3):376-394. (PMID: 27812306)
      Autoimmun Rev. 2021 Mar;20(3):102759. (PMID: 33476813)
      Intern Emerg Med. 2021 Mar;16(2):269-271. (PMID: 33385295)
      QJM. 1995 Feb;88(2):127-33. (PMID: 7704563)
      Autoimmun Rev. 2022 Jun;21(6):103100. (PMID: 35452854)
      Am J Kidney Dis. 2020 Jan;75(1):124-137. (PMID: 31358311)
      Biochem Med (Zagreb). 2021 Jun 15;31(2):020502. (PMID: 33927550)
      Nat Rev Rheumatol. 2014 Aug;10(8):494-501. (PMID: 24890776)
      Lupus. 2016 Jul;25(8):917-24. (PMID: 27252270)
      Autoimmun Rev. 2021 Jan;20(1):102716. (PMID: 33197574)
      Clin Exp Rheumatol. 2014 May-Jun;32(3 Suppl 82):S112-7. (PMID: 24854381)
      Auto Immun Highlights. 2020 Feb 6;11(1):4. (PMID: 32127033)
      Clin Biochem. 2017 Dec;50(18):1306-1311. (PMID: 28847718)
      J Rheumatol. 2001 Jul;28(7):1584-90. (PMID: 11469466)
      Clin Chem Lab Med. 2019 Jul 26;57(8):1197-1206. (PMID: 30789822)
      Ann Rheum Dis. 2020 Nov;79(11):1520-1522. (PMID: 32546601)
      Nat Rev Rheumatol. 2017 Nov;13(11):683-692. (PMID: 28905856)
      Auto Immun Highlights. 2020 Sep 3;11(1):12. (PMID: 32883353)
      Autoimmun Rev. 2009 Jun;8(7):543-8. (PMID: 19200856)
      Front Immunol. 2021 Mar 16;12:656796. (PMID: 33796118)
      Autoimmun Rev. 2020 Sep;19(9):102618. (PMID: 32663621)
      Clin Chem. 2024 Mar 2;70(3):482-485. (PMID: 38300842)
      Clin Lab Med. 2019 Dec;39(4):539-552. (PMID: 31668268)
      Am J Clin Pathol. 2003 Sep;120(3):312-8. (PMID: 14502794)
      Clin Biochem. 2020 Sep;83:57-64. (PMID: 32505738)
      Am J Clin Pathol. 1999 Apr;111(4):507-13. (PMID: 10191771)
      Arthritis Rheum. 2013 Jan;65(1):1-11. (PMID: 23045170)
    • Contributed Indexing:
      Keywords: antineutrophil cytoplasmic antibodies; autoimmunity; harmonization; recommendations
    • Accession Number:
      0 (Antibodies, Antineutrophil Cytoplasmic)
      EC 1.11.1.7 (Peroxidase)
    • Publication Date:
      Date Created: 20250616 Date Completed: 20250616 Latest Revision: 20250617
    • Publication Date:
      20260130
    • Accession Number:
      PMC12161514
    • Accession Number:
      10.11613/BM.2025.020706
    • Accession Number:
      40520655